What is Sidoti Csr’s Forecast for USNA Q1 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti Csr lowered their Q1 2025 earnings per share estimates for USANA Health Sciences in a research note issued to investors on Thursday, April 17th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.70 for the quarter, down from their previous estimate of $0.71. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.67 EPS, FY2025 earnings at $2.59 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.39 EPS.

Other analysts have also recently issued reports about the stock. DA Davidson lowered their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Finally, Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.

USANA Health Sciences Price Performance

NYSE:USNA opened at $23.75 on Friday. The firm has a market cap of $448.90 million, a PE ratio of 8.39, a P/E/G ratio of 0.93 and a beta of 1.00. The firm has a 50 day simple moving average of $28.44 and a 200-day simple moving average of $33.57. USANA Health Sciences has a 1-year low of $23.26 and a 1-year high of $49.78.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of USNA. State Street Corp raised its stake in shares of USANA Health Sciences by 0.6% in the 3rd quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after acquiring an additional 2,782 shares during the period. Barclays PLC increased its holdings in USANA Health Sciences by 111.9% in the 3rd quarter. Barclays PLC now owns 27,737 shares of the company’s stock valued at $1,052,000 after purchasing an additional 14,647 shares in the last quarter. Geode Capital Management LLC raised its position in USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after purchasing an additional 12,898 shares during the period. Franklin Resources Inc. lifted its stake in shares of USANA Health Sciences by 9.2% during the third quarter. Franklin Resources Inc. now owns 21,050 shares of the company’s stock worth $750,000 after purchasing an additional 1,771 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of USANA Health Sciences by 5.7% in the fourth quarter. Nordea Investment Management AB now owns 50,450 shares of the company’s stock worth $1,814,000 after buying an additional 2,723 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Joshua Foukas sold 5,732 shares of USANA Health Sciences stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the sale, the chief executive officer now owns 15,716 shares of the company’s stock, valued at $463,150.52. The trade was a 24.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,920 shares of company stock valued at $500,285. Insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.